| “The court tries to turn back the clock on medical science and prevent doctors from following current medical evidence,” said Jennifer Dalven, director of the American Civil Liberties Union’s Reproductive Freedom Project, in a statement.
Despite the ruling, nothing about the way mifepristone is prescribed or dispensed must change immediately. “Although the appeals court would make access to the drug more restrictive, including by requiring in-person dispensing again, an earlier U.S. Supreme Court order means that the ruling does nothing to change mifepristone’s accessibility,” explains law blogger Chris Geidner. “The drug remains available on current terms.”
The new ruling stems from a case brought in Texas by the Alliance for Hippocratic Medicine. In April, U.S. District Judge Matthew Kacsmaryk ruled in the group’s favor, holding that the FDA erred in approving mifepristone more than two decades ago and when it later loosened prescribing restrictions.
Kacsmaryk said that access to the drug should be suspended. On the same day, however, a federal judge in Washington state held that federal authorities should not restrict access to mifepristone.
Meanwhile, the Department of Justice appealed the anti-mifepristone ruling. And the 5th Circuit partially paused the lower court’s decision pending the appeals court’s ruling on the merits of the case. “Basically, the [5th Circuit] panel stayed those portions of the order suspending the FDA’s 2000 approval of mifepristone, but not those concerning actions taken by FDA concerning mifepristone in 2016 or later,” explained Jonathan Adler at The Volokh Conspiracy.
The Supreme Court waded into the controversy in late April, granting the government’s request for a stay “pending disposition of the appeal in the United States Court of Appeals for the Fifth Circuit” and halting any implementation of future rulings on the case pending Supreme Court review.
The case is now in the Supreme Court’s hands.
“Under the Supreme Court’s [April] order, the Fifth Circuit’s decision would go into effect either if the Supreme Court doesn’t take up the case on appeal or if it takes the case and affirms the Fifth Circuit,” Geidner explains.
Notably, the 5th Circuit avoided ruling on Comstock Act claims, which had been part of the Alliance for Hippocratic Medicine’s initial challenge and Kacsmaryk’s order.
“Originally passed in 1873 and named for an anti-vice crusader, the Comstock Act was intended to prohibit the mailing of contraceptives, ‘lewd’ writings and any ‘instrument, substance, drug, medicine, or thing’ that could be used in an abortion,” explains PBS.
Kacsmaryk agreed with the Alliance for Hippocratic Medicine that the Comstock Act bans the mailing of mifepristone. Allowing the “dispensing of chemical abortion drugs through mail violates unambiguous federal criminal law,” he wrote. The FDA’s 2021 guidance saying mifepristone needn’t be prescribed in person was also “arbitrary and capricious,” Kacsmaryk held.
Agreeing with the “arbitrary and capricious” part of Kacsmaryk’s order there, the 5th Circuit “did not consider the Comstock Act claim raised by the challengers — a claim that has gotten significant attention due to its potentially wide-reaching effects,” notes Geidner. |